• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血糖正常个体中代谢功能障碍相关脂肪性肝病与胰岛素抵抗之间的关联

Association between metabolic dysfunction-associated steatotic liver disease and insulin resistance in individuals with normoglycemia.

作者信息

Liao Nai-Hui, Wang Chun-Yi, Lai Kuan-Yu, Kao Hsiang-Han, Lin Wen-Yuan, Chen Tsung-Po

机构信息

Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.

School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.

出版信息

Medicine (Baltimore). 2025 Aug 22;104(34):e44109. doi: 10.1097/MD.0000000000044109.

DOI:10.1097/MD.0000000000044109
PMID:40859520
Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent, especially among individuals with type 2 diabetes mellitus. Insulin resistance (IR) is a key shared mechanism. This study aimed to investigate the association between MASLD and IR in individuals with normal glucose levels. We recruited participants from communities and outpatient clinics in central and northern Taiwan, excluding those with impaired fasting glucose or type 2 diabetes mellitus. Data collected included body mass index, blood pressure, body fat percentage, and lifestyle factors. After overnight fasting, blood samples were taken. MASLD was diagnosed via abdominal ultrasonography. IR was calculated using the homeostasis model assessment of insulin resistance formula and categorized into tertiles (T1-T3). Statistical analyses included analysis of variance and multivariate logistic regression. Among 485 participants (mean age 42.0 ± 11.4 years), MASLD prevalence increased with IR levels (T1: 34.1%, T2: 40.1%, T3: 47.8%; P < .001). Fasting glucose remained within normal limits but rose with IR (T1: 81.9 ± 7.4, T2: 85.1 ± 7.6, T3: 87.3 ± 6.5 mg/dL; P < .0001). After adjusting for age, sex, body mass index, exercise, alcohol use, and smoking, MASLD risk was significantly higher in T3 (odds ratio: 3.87, 95% confidence interval: 2.08-7.21) and T2 (odds ratio: 1.83, 95% confidence interval: 1.11-3.00) compared to T1. Even among individuals with normal glucose levels, elevated IR is significantly associated with higher MASLD risk. Early identification and intervention for IR may help prevent MASLD progression.

摘要

代谢功能障碍相关脂肪性肝病(MASLD)日益普遍,尤其是在2型糖尿病患者中。胰岛素抵抗(IR)是一个关键的共同机制。本研究旨在调查血糖水平正常个体中MASLD与IR之间的关联。我们从台湾中部和北部的社区及门诊招募参与者,排除空腹血糖受损或2型糖尿病患者。收集的数据包括体重指数、血压、体脂百分比和生活方式因素。过夜禁食后采集血样。通过腹部超声诊断MASLD。使用胰岛素抵抗稳态模型评估公式计算IR,并分为三分位数(T1 - T3)。统计分析包括方差分析和多因素逻辑回归。在485名参与者(平均年龄42.0±11.4岁)中,MASLD患病率随IR水平升高而增加(T1:34.1%,T2:40.1%,T3:47.8%;P <.001)。空腹血糖保持在正常范围内,但随IR升高(T1:81.9±7.4,T2:85.1±7.6,T3:87.3±6.5mg/dL;P <.0001)。在调整年龄、性别、体重指数、运动、饮酒和吸烟因素后,与T1相比,T3(优势比:3.87,95%置信区间:2.08 - 7.21)和T2(优势比:1.83,95%置信区间:1.11 - 3.00)患MASLD的风险显著更高。即使在血糖水平正常的个体中,IR升高也与更高的MASLD风险显著相关。早期识别和干预IR可能有助于预防MASLD进展。

相似文献

1
Association between metabolic dysfunction-associated steatotic liver disease and insulin resistance in individuals with normoglycemia.血糖正常个体中代谢功能障碍相关脂肪性肝病与胰岛素抵抗之间的关联
Medicine (Baltimore). 2025 Aug 22;104(34):e44109. doi: 10.1097/MD.0000000000044109.
2
Nonalcoholic Fatty Liver非酒精性脂肪肝
3
Association between estimated glucose disposal rate and cardiovascular disease prevalence and mortality outcomes in metabolic dysfunction-associated steatotic liver disease: a comparative analysis of insulin resistance markers.代谢功能障碍相关脂肪性肝病中估计的葡萄糖处置率与心血管疾病患病率和死亡率结局之间的关联:胰岛素抵抗标志物的比较分析
J Glob Health. 2025 Aug 4;15:04249. doi: 10.7189/jogh.15.04249.
4
Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity.血糖异常和肝脏脂质含量决定了肥胖症中胰岛素抵抗与肝脏氧化磷酸化能力之间的关系。
J Hepatol. 2025 Mar;82(3):417-426. doi: 10.1016/j.jhep.2024.08.012. Epub 2024 Aug 31.
5
Glycemic variability in type 2 diabetic patients with metabolic dysfunction-associated steatotic liver disease: a case-control study.2型糖尿病合并代谢功能障碍相关脂肪性肝病患者的血糖变异性:一项病例对照研究。
Ann Med. 2025 Dec;57(1):2548976. doi: 10.1080/07853890.2025.2548976. Epub 2025 Aug 20.
6
Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study.1型糖尿病成人患者在接受振动控制瞬时弹性成像检查时,连续血糖监测指标与代谢功能障碍相关脂肪性肝病之间的关联:一项多中心横断面研究
Diabetes Metab. 2025 Sep;51(5):101684. doi: 10.1016/j.diabet.2025.101684. Epub 2025 Jul 5.
7
The serum uric acid to apolipoprotein A1 ratio is independently correlated with metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: findings from a single national metabolic management center cohort.血清尿酸与载脂蛋白A1比值与2型糖尿病中代谢功能障碍相关脂肪性肝病独立相关:来自单一国家代谢管理中心队列的研究结果
Front Endocrinol (Lausanne). 2025 Jun 4;16:1619003. doi: 10.3389/fendo.2025.1619003. eCollection 2025.
8
The role of irregular eating behaviors in metabolic dysfunction-associated steatotic liver disease: evidence from a multicenter cross-sectional study in China.不规律饮食行为在代谢功能障碍相关脂肪性肝病中的作用:来自中国一项多中心横断面研究的证据
J Transl Med. 2025 Aug 2;23(1):859. doi: 10.1186/s12967-025-06870-z.
9
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.代谢功能障碍相关脂肪性肝病:肌肉与体重的故事。
World J Gastroenterol. 2025 May 28;31(20):105346. doi: 10.3748/wjg.v31.i20.105346.
10
Dietary lipophilic index and odds of metabolic dysfunction-associated steatotic liver disease (MASLD): A population-based study.饮食亲脂性指数与代谢功能障碍相关脂肪性肝病(MASLD)的患病几率:一项基于人群的研究。
Dig Liver Dis. 2025 Jul;57(7):1455-1464. doi: 10.1016/j.dld.2025.04.001. Epub 2025 May 13.

本文引用的文献

1
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025.4. 合并症的综合医学评估与评定:2025年糖尿病照护标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S59-S85. doi: 10.2337/dc25-S004.
2
From NAFLD to MASLD: Promise and pitfalls of a new definition.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病:新定义的前景与陷阱
J Hepatol. 2024 Jul;81(1):e18-e19. doi: 10.1016/j.jhep.2023.09.038. Epub 2023 Dec 19.
3
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care.
胰岛素抵抗在2型糖尿病患者非酒精性脂肪性肝病发生发展中的作用:从实验室到患者护理
Diabetes Spectr. 2024 Winter;37(1):20-28. doi: 10.2337/dsi23-0013. Epub 2024 Feb 15.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
5
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.NASH 的抗炎和抗纤维化治疗靶点的综合观点。
J Hepatol. 2023 Aug;79(2):552-566. doi: 10.1016/j.jhep.2023.03.038. Epub 2023 Apr 14.
6
Approach to the Patient With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者的诊疗方法
J Clin Endocrinol Metab. 2023 Jan 17;108(2):483-495. doi: 10.1210/clinem/dgac624.
7
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).美国临床内分泌学会临床实践指南:原发性保健和内分泌学临床环境中非酒精性脂肪性肝病的诊断和管理:由美国肝病研究协会(AASLD)共同赞助。
Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.
8
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.2 型糖尿病会增加肥胖和非酒精性脂肪性肝病患者发生肝纤维化的风险。
Obesity (Silver Spring). 2021 Nov;29(11):1950-1960. doi: 10.1002/oby.23263. Epub 2021 Sep 23.
9
Mechanisms and disease consequences of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的机制及疾病后果
Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.
10
Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat.代谢健康型肥胖与非酒精性脂肪性肝病严重程度的关系,独立于内脏脂肪。
J Gastroenterol Hepatol. 2021 Oct;36(10):2903-2910. doi: 10.1111/jgh.15544. Epub 2021 May 31.